OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CHARACTERIZATION OF EVOLVING LESIONS IN FELLOW EYES OF EXUDATIVE TYPE 3 MACULAR NEOVASCULARIZATION PATIENTS
-
- Riccardo Sacconi
- School of Medicine, Vita-Salute San Raffaele University, Milan, Italy;
-
- Paolo Forte
- School of Medicine, Vita-Salute San Raffaele University, Milan, Italy;
-
- Vittorio Capuano
- Clinical Research Center, GRC Macula, and Biological Ressources Center, Creteil, France;
-
- Alexandra Miere
- Clinical Research Center, GRC Macula, and Biological Ressources Center, Creteil, France;
-
- Eliana Costanzo
- Foundation G.B. Bietti-IRCCS, Rome, Italy.
-
- Beatrice Tombolini
- School of Medicine, Vita-Salute San Raffaele University, Milan, Italy;
-
- Federico Fantaguzzi
- School of Medicine, Vita-Salute San Raffaele University, Milan, Italy;
-
- Camille Jung
- Clinical Research Center, GRC Macula, and Biological Ressources Center, Creteil, France;
-
- Mariacristina Parravano
- Foundation G.B. Bietti-IRCCS, Rome, Italy.
-
- Monica Varano
- Foundation G.B. Bietti-IRCCS, Rome, Italy.
-
- Eric Souied
- Clinical Research Center, GRC Macula, and Biological Ressources Center, Creteil, France;
-
- Francesco Bandello
- School of Medicine, Vita-Salute San Raffaele University, Milan, Italy;
-
- Giuseppe Querques
- School of Medicine, Vita-Salute San Raffaele University, Milan, Italy;
Abstract
<jats:sec> <jats:title>Purpose:</jats:title> <jats:p>To investigate fellow eyes of newly diagnosed unilateral exudative Type 3 (T3) macular neovascularization (MNV) patients by assessing the presence and progression of a preclinical neovascular component during a 3-year follow-up.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>This is a longitudinal study involving three retinal referral centers. Patients affected by unilateral exudative treatment-naive T3 MNV were enrolled.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>Twenty-four eyes of 24 patients (79 ± 6 years old) were enrolled. Nine eyes (37%) displayed a nonexudative T3 MNV at baseline that developed exudation after a mean of 9 ± 9 months. Fifteen eyes that did not display a nonexudative Type 3 MNV at baseline. Five eyes (21%) did not display neovessels at baseline, but showed a nonexudative T3 after 13 ± 9 months, and exudation after 8 ± 3 months. Five eyes (21%) developed active exudative T3 MNV after 23 ± 9 months, with no detectable nonexudative stage at baseline. Five eyes (21%) did not show MNV, but progressed to geographic atrophy by 36 months of follow-up. Overall, T3 MNV in the fellow eye accounted for 79%, all developing exudation over 3 years of follow-up.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion:</jats:title> <jats:p>The occurrence of a nonexudative T3 MNV is a frequent event in the fellow eye of patients newly diagnosed with unilateral exudative T3 MNV and it precedes the development of exudation over 3 years (prevalence of 37% and cumulative incidence of 79%). Optical coherence tomography angiography approach may be used to perform an early diagnosis and treatment of patients with T3 MNV.</jats:p> </jats:sec>
Journal
-
- Retina
-
Retina 42 (11), 2075-2082, 2022-11
Ovid Technologies (Wolters Kluwer Health)
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1360298760952015616
-
- ISSN
- 0275004X
-
- Data Source
-
- Crossref